Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 72

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 72
---
 tool because they motivate our executive officers to increase shareholder value and remain with the Company.

In determining the value and form of long-term incentive compensation to be provided to each named

| 42 |     | 2025 PROXY STATEMENT |

TABLE OF CONTENTS

| COMPENSATION DISCUSSION AND ANALYSIS |

executive officer in February 2024, the Committee considered Pay Governance’s market data, including:

• The prevalence of other forms of equity-based incentive compensation used by the peer group companies;

• For each executive officer, the grant date Black-Scholes value of the annual stock option awarded to the executive officer in 2023;

• For each executive officer and all executive officers as a whole, the annual stock options awarded in 2023 as a percent of the Company's outstanding shares, with comparisons to the peer group data for that year;

• For all executive officers as a whole, the grant-date values of the annual stock options awarded in 2023, with comparisons to the peer group data for that year;

• Executive officers' individual and collective equity "ownership" through vested and unvested stock options relative to the peer group data, and the unvested value as a multiple of the estimated value of a new hire award which would be required to replace each named executive officer;

• Other market data on equity compensation practices, including with respect to "burn rate" and dilution ("overhang"); and

• Each executive officer's total targeted direct compensation relative to the peer group data.

The Committee also considered the relative position, experience, performance, and criticality of each named executive officer. The Committee considered it critical to retain these executive officers to meet 2024 and longer-term objectives and decided that time-vested stock options continued to be the best vehicle to serve that retention need.

Based on all the above considerations, in 2024, the Committee approved annual stock option awards to

each of our named executive officers other than Dr. Kinney, i.e., Mr. Nguyen, Mr. Smith, Ms. Karp, and Dr. Zago, and the Board approved an annual stock option award for Dr. Kinney. Those stock options vest as to 25% of the shares subject to the option on the first anniversary of the grant date and as to 1/48 th of the shares subject to the option on each monthly anniversary thereafter, subject to continued employment on each applicable vesting date (except in the event of certain terminations of employment, as described below under the heading